Jeffrey A. Bubis

573 total citations
14 papers, 388 citations indexed

About

Jeffrey A. Bubis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jeffrey A. Bubis has authored 14 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 4 papers in Surgery. Recurrent topics in Jeffrey A. Bubis's work include Esophageal Cancer Research and Treatment (4 papers), Cancer therapeutics and mechanisms (3 papers) and Complement system in diseases (3 papers). Jeffrey A. Bubis is often cited by papers focused on Esophageal Cancer Research and Treatment (4 papers), Cancer therapeutics and mechanisms (3 papers) and Complement system in diseases (3 papers). Jeffrey A. Bubis collaborates with scholars based in United States, Germany and Belgium. Jeffrey A. Bubis's co-authors include Martin Steins, Joachim von Pawel, Martin Reck, Frances A. Shepherd, J. Mezger, Manuel Dómine, Mark A. Socinski, Paul Lorigan, Robert M. Jotte and David R. Spigel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Thoracic Oncology.

In The Last Decade

Jeffrey A. Bubis

14 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey A. Bubis United States 7 277 232 136 78 76 14 388
MA Gertz United States 7 204 0.7× 50 0.2× 268 2.0× 57 0.7× 34 0.4× 7 499
Seshadri Thirumala United States 9 79 0.3× 21 0.1× 83 0.6× 76 1.0× 95 1.3× 21 280
Laetitia Coutte France 5 268 1.0× 31 0.1× 64 0.5× 53 0.7× 61 0.8× 10 386
MQ Lacy United States 11 229 0.8× 37 0.2× 347 2.6× 16 0.2× 36 0.5× 11 517
Ting‐Jung Wu Taiwan 11 94 0.3× 112 0.5× 82 0.6× 69 0.9× 20 0.3× 21 359
John M. Richart United States 8 154 0.6× 28 0.1× 68 0.5× 59 0.8× 109 1.4× 21 280
Tomoyuki Sasaki Japan 8 108 0.4× 15 0.1× 81 0.6× 35 0.4× 76 1.0× 16 268
Mary McCauley United States 7 129 0.5× 59 0.3× 60 0.4× 58 0.7× 97 1.3× 13 306
Norio Hanata Japan 9 42 0.2× 35 0.2× 46 0.3× 53 0.7× 130 1.7× 18 255
P. Townley United States 6 293 1.1× 153 0.7× 100 0.7× 85 1.1× 15 0.2× 12 336

Countries citing papers authored by Jeffrey A. Bubis

Since Specialization
Citations

This map shows the geographic impact of Jeffrey A. Bubis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Bubis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Bubis more than expected).

Fields of papers citing papers by Jeffrey A. Bubis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Bubis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Bubis. The network helps show where Jeffrey A. Bubis may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Bubis

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Bubis. A scholar is included among the top collaborators of Jeffrey A. Bubis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Bubis. Jeffrey A. Bubis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Strickler, John H., Cynthia A. Sirard, Jason Baum, et al.. (2024). DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.. Journal of Clinical Oncology. 42(3_suppl). 104–104. 2 indexed citations
2.
Pawel, Joachim von, Robert M. Jotte, David R. Spigel, et al.. (2014). Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology. 32(35). 4012–4019. 232 indexed citations
3.
Wood, Matthew D., Bassem I. Zaki, Stuart R. Gordon, et al.. (2013). Trimodality Therapy for Stage II–III Carcinoma of the Esophagus: A Dose-Ranging Study of Concurrent Capecitabine, Docetaxel, and Thoracic Radiotherapy. Journal of Thoracic Oncology. 8(4). 487–494. 7 indexed citations
4.
Raza, Azra, Farhad Ravandi, Anjay Rastogi, et al.. (2013). A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. Cytometry Part B Clinical Cytometry. n/a–n/a. 24 indexed citations
5.
Raza, Azra, Farhad Ravandi, Anjay Rastogi, et al.. (2013). A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytometry Part B Clinical Cytometry. 86(3). 175–182. 42 indexed citations
6.
Pawel, Joachim von, Robert M. Jotte, Eugene Paschold, et al.. (2012). Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC). Pneumologie. 66(S 01). 2 indexed citations
7.
Oudard, Stéphane, Lisa Sengeløv, Paul N. Mainwaring, et al.. (2012). First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.. Journal of Clinical Oncology. 30(15_suppl). TPS4696–TPS4696. 3 indexed citations
8.
Jotte, Robert M., Joachim von Pawel, David R. Spigel, et al.. (2011). Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).. Journal of Clinical Oncology. 29(15_suppl). 7000–7000. 40 indexed citations
9.
10.
Rigas, James R., Konstantin H. Dragnev, & Jeffrey A. Bubis. (2005). Docetaxel in the Treatment of Esophageal Cancer. Seminars in Oncology. 32(2 Suppl 4). 39–51. 21 indexed citations
11.
Bubis, Jeffrey A., Pamela Ely, Kenneth R. Meehan, et al.. (2005). Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes.. Blood. 106(11). 4633–4633. 2 indexed citations
12.
Bubis, Jeffrey A., et al.. (2005). Subcutaneous Administration of Alemtuzumab: A Single Institution Experience.. Blood. 106(11). 5029–5029. 2 indexed citations
13.
Bubis, Jeffrey A., Ian Williams, J. E. G. Sutton, et al.. (2004). Docetaxel (DTX) and carboplatin (CP) followed by a dose-ranging study of oral capecitabine, weekly DTX, concomitant radiotherapy and surgery for the treatment of patients with stage II-III carcinoma of the esophagus. Journal of Clinical Oncology. 22(14_suppl). 4049–4049. 1 indexed citations
14.
Bubis, Jeffrey A., Ian Williams, Konstantin H. Dragnev, et al.. (2004). Docetaxel (DTX) and carboplatin (CP) followed by a dose-ranging study of oral capecitabine, weekly DTX, concomitant radiotherapy and surgery for the treatment of patients with stage II-III carcinoma of the esophagus. Journal of Clinical Oncology. 22(14_suppl). 4049–4049. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by MA Gertz Breakdown of academic impact, for papers by Seshadri Thirumala Breakdown of academic impact, for papers by Laetitia Coutte Breakdown of academic impact, for papers by MQ Lacy Breakdown of academic impact, for papers by Ting‐Jung Wu Breakdown of academic impact, for papers by John M. Richart Breakdown of academic impact, for papers by Tomoyuki Sasaki Breakdown of academic impact, for papers by Mary McCauley Breakdown of academic impact, for papers by Norio Hanata Breakdown of academic impact, for papers by P. Townley
Rankless by CCL
2026